tofacitinib and Leukemia--Prolymphocytic--T-Cell

tofacitinib has been researched along with Leukemia--Prolymphocytic--T-Cell* in 1 studies

Other Studies

1 other study(ies) available for tofacitinib and Leukemia--Prolymphocytic--T-Cell

Article	Year
Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation. Leukemia & lymphoma, 2019, Volume: 60, Issue:7 Topics: Drug Resistance, Neoplasm; Drug Therapy, Combination; Humans; Janus Kinase 1; Janus Kinase 2; Janus Kinase 3; Leukemia, Prolymphocytic, T-Cell; Male; Middle Aged; Mutation; Nitriles; Piperidines; Prognosis; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Pyrroles	2019

Article

Year

Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation.

Leukemia & lymphoma, 2019, Volume: 60, Issue:7

Topics: Drug Resistance, Neoplasm; Drug Therapy, Combination; Humans; Janus Kinase 1; Janus Kinase 2; Janus Kinase 3; Leukemia, Prolymphocytic, T-Cell; Male; Middle Aged; Mutation; Nitriles; Piperidines; Prognosis; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Pyrroles

2019